Europe Microbiome Therapeutics Market Size & Outlook
Europe microbiome therapeutics market, 2018-2030 (US$M)
Related Markets
Europe microbiome therapeutics market highlights
- The Europe microbiome therapeutics market generated a revenue of USD 10.3 million in 2022.
- The market is expected to grow at a CAGR of 35.4% from 2023 to 2030.
- In terms of segment, c. difficile was the largest revenue generating application in 2022.
- C. difficile is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2023 to 2030.
Europe data book summary
| Market revenue in 2022 | USD 10.3 million |
| Market revenue in 2030 | USD 116.2 million |
| Growth rate | 35.4% (CAGR from 2022 to 2030) |
| Largest segment | C. difficile |
| Fastest growing segment | C. difficile |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | C. difficile, Crohns disease, Inflammatory Bowel Disease, Diabetes |
| Key market players worldwide | Finch Therapeutics Group Inc, Vedanta |
Other key industry trends
- In terms of revenue, Europe region accounted for 10.8% of the global microbiome therapeutics market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 901.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Microbiome Therapeutics Market Scope
Microbiome Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe microbiome therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to microbiome therapeutics market will help companies and investors design strategic landscapes.
C. difficile was the largest segment with a revenue share of 83.5% in 2022. Horizon Databook has segmented the Europe microbiome therapeutics market based on c. difficile, crohns disease, inflammatory bowel disease, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
The microbiome therapeutics market in Europe is growing owing to increasing research into the role of the human microbiome in health and disease. This has led to the development of new therapies and diagnostic tools aimed at manipulating the microbiome to treat a range of diseases, including gastrointestinal disorders, immune-mediated diseases, and neurological disorders.
Despite these trends, the Europe microbiome therapeutics market still faces several challenges, including the need for large-scale clinical trials to demonstrate the safety and efficacy of these therapies and the complex regulatory environment.
Reasons to subscribe to Europe microbiome therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe microbiome therapeutics market databook
-
Our clientele includes a mix of microbiome therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe microbiome therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Europe microbiome therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe microbiome therapeutics market size, by country, 2018-2030 (US$M)
Europe Microbiome Therapeutics Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
